Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
More trials urged
Basel, Switzerland - Completely resected high-risk malignant melanoma patients who were treated with adjuvant extended-duration low-dose interferon did not have a significant survival benefit over patients who were only observed after surgery to remove the cancer, according to a new study.
Recent Videos
Related Content
